98 related articles for article (PubMed ID: 1375277)
1. Antibodies are produced to the variable regions of the external envelope glycoprotein of human immunodeficiency virus type 1 in chimpanzees infected with the virus and baboons immunized with a candidate recombinant vaccine.
Stephens DM; Eichberg JW; Haigwood NL; Steimer KS; Davis D; Lachmann PJ
J Gen Virol; 1992 May; 73 ( Pt 5)():1099-106. PubMed ID: 1375277
[TBL] [Abstract][Full Text] [Related]
2. B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides.
Neurath AR; Strick N; Lee ES
J Gen Virol; 1990 Jan; 71 ( Pt 1)():85-95. PubMed ID: 1689372
[TBL] [Abstract][Full Text] [Related]
3. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
Steimer KS; Haigwood NL
Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
[TBL] [Abstract][Full Text] [Related]
4. Fine specificity of anti-V3 antibodies induced in chimpanzees by HIV candidate vaccines.
Coëffier E; Girard M; Barré-Sinoussi F; Meignier B; Muchmore E; Fultz PN; LeClerc C
AIDS Res Hum Retroviruses; 1998 Aug; 14(12):1023-34. PubMed ID: 9718117
[TBL] [Abstract][Full Text] [Related]
5. Multiepitope vaccines intensively increased levels of antibodies recognizing three neutralizing epitopes on human immunodeficiency virus-1 envelope protein.
Lu Y; Xiao Y; Ding J; Dierich MP; Chen YH
Scand J Immunol; 2000 May; 51(5):497-501. PubMed ID: 10792842
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the immune response to recombinant gp120 in humans and chimpanzees.
Berman PW; Eastman DJ; Wilkes DM; Nakamura GR; Gregory TJ; Schwartz D; Gorse G; Belshe R; Clements ML; Byrn RA
AIDS; 1994 May; 8(5):591-601. PubMed ID: 7520248
[TBL] [Abstract][Full Text] [Related]
7. Specificity of chimpanzee antibodies binding a strain-specific HIV-1 neutralization epitope of the external envelope.
Goudsmit J; Bakker M; Smit L; Meloen RH
J Med Primatol; 1989; 18(3-4):357-62. PubMed ID: 2474656
[TBL] [Abstract][Full Text] [Related]
8. Search for epitope-specific antibody responses to the human immunodeficiency virus (HIV-1) envelope glycoproteins signifying resistance to disease development.
Neurath AR; Strick N; Taylor P; Rubinstein P; Stevens CE
AIDS Res Hum Retroviruses; 1990 Oct; 6(10):1183-92. PubMed ID: 1701315
[TBL] [Abstract][Full Text] [Related]
9. Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope.
Davis D; Stephens DM; Carne CA; Lachmann PJ
J Gen Virol; 1993 Dec; 74 ( Pt 12)():2609-17. PubMed ID: 7506300
[TBL] [Abstract][Full Text] [Related]
10. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
11. Human immunodeficiency virus type 1 subtype E envelope recombinant peptides containing naturally immunogenic epitopes.
Chang SY; Vithayasai V; Vithayasai P; Essex M; Lee TH
J Infect Dis; 2000 Aug; 182(2):442-50. PubMed ID: 10915074
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and specificity of the candidate multi-epitope-vaccines against HIV-1.
Lu Y; Ding J; Chen YH
Immunopharmacol Immunotoxicol; 2001 Nov; 23(4):487-94. PubMed ID: 11792008
[TBL] [Abstract][Full Text] [Related]
13. Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein.
Haynes BF; Arthur LO; Frost P; Matthews TJ; Langlois AJ; Palker TJ; Hart MK; Scearce RM; Jones DM; McDanal C
J Exp Med; 1993 Mar; 177(3):717-27. PubMed ID: 7679708
[TBL] [Abstract][Full Text] [Related]
14. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression.
Zwart G; van der Hoek L; Valk M; Cornelissen MT; Baan E; Dekker J; Koot M; Kuiken CL; Goudsmit J
Virology; 1994 Jun; 201(2):285-93. PubMed ID: 7514319
[TBL] [Abstract][Full Text] [Related]
15. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
16. Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate.
Chen CH; Jin L; Zhu C; Holz-Smith S; Matthews TJ
J Virol; 2001 Jul; 75(14):6700-4. PubMed ID: 11413338
[TBL] [Abstract][Full Text] [Related]
17. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.
Goudsmit J; Debouck C; Meloen RH; Smit L; Bakker M; Asher DM; Wolff AV; Gibbs CJ; Gajdusek DC
Proc Natl Acad Sci U S A; 1988 Jun; 85(12):4478-82. PubMed ID: 2454471
[TBL] [Abstract][Full Text] [Related]
18. Epitopes of HIV-1 glycoproteins recognized by the human immune system.
Laal S; Zolla-Pazner S
Chem Immunol; 1993; 56():91-111. PubMed ID: 7680869
[No Abstract] [Full Text] [Related]
19. Variable epitope libraries: new vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response.
Charles-Niño C; Pedroza-Roldan C; Viveros M; Gevorkian G; Manoutcharian K
Vaccine; 2011 Jul; 29(32):5313-21. PubMed ID: 21600948
[TBL] [Abstract][Full Text] [Related]
20. Humoral responses to linear epitopes on the HIV-1 envelope in seropositive volunteers after vaccine therapy with rgp160.
Loomis LD; Deal CD; Kersey KS; Burke DS; Redfield RR; Birx DL
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):13-26. PubMed ID: 7544225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
